Pharma ADMET Testing Market Forecast to 2028

Pharma ADMET Testing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Testing Type (In Vivo ADMET Testing, In Vitro ADMET Testing, and In Silico ADMET Testing), Technology (Cell Culture, High Throughput, Molecular Imaging, and OMICS Technology), and Application (Systemic Toxicity, Renal Toxicity, Hepatotoxicity, Neurotoxicity, and Others)

Report Code : TIPRE00029509 | Region : Global | Industry : Pharmaceuticals | Published Date : 15/Jul/2022

The pharma ADMET testing market is expected to grow from US$ 6,783.06 million in 2021 to US$ 13,578.62 million by 2028; it is estimated to grow at a CAGR of 10.5% from 2022 to 2028.

The report highlights trends prevailing in the market and factors driving the market growth. The market growth is attributed to the high rate of late-stage drug failure and the increasing number of products approvals and launches. Additionally, the rise of new and emerging technologies is likely to emerge as a significant trend in the market during the forecast period. However, the high cost of ADME testing studies limits the market growth.

ADMET (absorption, distribution, metabolism, excretion, and toxicology) testing plays a critical role in drug discovery and development to understand the pharmacokinetic and pharmacodynamic properties of a drug. The testing prevents the chances of drug failure during the drug discovery phase. Thus, ADMET testing facilitates pharmaceutical companies to minimize drug discovery time, testing complications, and drug development cost.

The pre-approval expenditures for a medicine can be as high as US$ 2.56 billion, which further increases to US$ 2.87 billion in the post-approved stage. According to the study titled “Why 90% of Clinical Drug Development Fails and How to Improve It?”, 2022, 90% of clinical drug development fails despite the successful implementation of many strategies. After entering clinical investigations, 9 out of 10 drug candidates fail during phase I, II, and III clinical trials, and the drug approval process. Drug candidates rejected in preclinical stages are not included in the 90% failure rate of the drugs in clinical stages, as they don’t enter the phase I clinical trials. If preclinical drug candidates are included, the failure rate of drug discovery and development rises even higher than 90%. According to analyses of clinical trial data from 2010 to 2017, lacking clinical effectiveness (40–50%), uncontrollable toxicity (30%), poor drug-like qualities (10–15%), no commercial needs, and ineffective strategic planning (10%) are the four major causes of trial failure.

New drug development is both resource and time-intensive, where later clinical stages result in significant costs. The discovery and development of each new medicine that is approved for clinical use is a lengthy, expensive, and challenging process that takes over 10–15 years and costs on average over US$ 1–2 billion. To lower the attrition rate in drug research & development, it is crucial to filter and optimize the absorption, distribution, metabolism, elimination, and toxicity (ADMET) characteristics of pharmaceuticals at an early stage. It has been widely accepted that drug ADMET properties should be considered as early as possible to reduce failure rates in the clinical phase of drug discovery. In vitro and in vivo drug evaluation techniques have reached maturity in preclinical applications, and in silico technologies are gaining vast acceptance to evaluate the relevant properties of drugs in the preclinical stage. The development of software programs and in silico models is further promoting the implementation of ADMET studies. Thus, the increasing need for ADME testing in drug development boosts the pharma ADMET testing market.

Based on testing type, the pharma ADMET testing market is segmented into in vivo ADMET testing, in vitro ADMET testing, and in silico ADMET testing. In 2021, the in vivo ADMET testing segment holds the largest market share. However, the in vitro ADMET testing segment is expected to register the highest CAGR from 2022 to 2028. Based on technology, the pharma ADMET testing market is segmented into cell culture, high throughput, molecular imaging, and OMICS technology. The cell culture segment held the largest market share in 2021. However, the high throughput segment is anticipated to register the highest CAGR during the forecast period. Based on application, the pharma ADMET testing market is segmented into systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and others. The systemic toxicity segment held the largest market share in 2021. However, the hepatotoxicity segment is anticipated to register the highest CAGR during 2022–2028.

Impact of COVID-19 Pandemic on Pharma ADMET Testing Market

The COVID-19 pandemic positively impacted the pharma ADMET testing market due to the increased number of researchers across APAC. During the pandemic, the demand for in vitro toxicology studies increased to study several drugs and vaccines. Additionally, the increased number of researches led to high utilization of technology instead of human resource to prevent the spread of novel coronavirus. Thus, the technology segment grew at an exponential level. Moreover, governments of APAC countries organized programs and open challenge events for researchers to come up with innovative drugs for COVID-19. Such events increased the overall research numbers due to the rise in government funding. Thus, the above-mentioned facts indicate the positive impact of COVID-19 pandemic on the pharma ADMET testing market.

Various organic and inorganic strategies are adopted by companies in the pharma ADMET testing market. The organic strategies mainly include product launches and product approvals. Further, inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help the market players in strengthening their customer base and expanding their product portfolios. A few of the significant developments by key players in the pharma ADMET testing market are listed below.

• In April 2022, Charles River Laboratories announced a collaboration with NCL to drive drug discovery projects toward finding innovative therapeutics. NLC utilizes its extensive biotech and pharmaceutical ecosystem and knowledge to carefully select high-potential, preclinical biotech research. Charles River’s comprehensive preclinical development services and strategy resources provide safe, high-quality drug discovery and development, which is supporting the projects of NLC’s portfolio companies together to bring life-saving drugs to patients.

• In March 2022, Promega Corporation (Promega) announced a collaboration with FUJIFILM Cellular Dynamics, Inc., for advancing novel assay development for drug discovery. Under a multi-year licensing agreement, FUJIFILM Cellular Dynamics will offer a wide range of custom differentiated induced pluripotent stem cell (iPSCs) integrated with Promega biosensor and intracellular bioluminescent reporter capabilities for researchers and scientists to use as a part of novel assay development in the drug discovery process.

The Canada Foundation for Innovation (CFI), Australian Research Council (ARC), National Institute of Health (NIH), World Health Organization (WHO), the Centers for Disease Control (CDC), and the Association of the British Pharmaceutical Industry (ABPI) are a few of the major primary and secondary sources referred to while preparing the report on the pharma ADMET testing market.

High Rate of Late-Stage Drug Failure Drives Pharma ADMET Testing Market Growth

The global pharma ADMET testing market is expected to grow from US$ 6,783.06 million in 2021 to US$ 13,578.62 million by 2028; it is estimated to grow at a CAGR of 10.5% from 2022 to 2028. The growth of the market is mainly driven by the high rates of late-stage drug failure and increasing approvals and launches of product. Additionally, the rise of new and emerging technologies is likely to emerge as a significant trend in the market during the forecast period. However, the high cost of ADME testing studies hampers the market growth.

ADMET (absorption, distribution, metabolism, excretion, and toxicity) testing is used to determine the safety, uptake, elimination, metabolic behavior, and effectiveness of drugs. Many drug candidates are not approved due to the lack of efficacy and safety. Therefore, testing drugs using ADMET testing becomes important as it helps find efficacious molecules. These drug tests define the impact of a specific drug or chemical on human tissues. Toxicology testing is an important phenomenon before introducing new medicine to the market. ADMET testing facilitates pharmaceutical manufacturing companies to minimize their drug discovery time and testing complications, and reduce the drug development cost.

The disaster of a rising number of therapeutic molecules in the last phases of clinical trials has cost money and valuable time invested in the research and development of new drugs. This has led to the high investments in the development of new technologies for toxicity testing. According to the article “Importance of ADME/Tox in Early Drug Discovery,” 2022, in the current drug discovery and development pipeline, only 10 molecules out of 1,000 screened hits are projected to enter the preclinical testing stage, and only 9.6% will enter clinical trials. The drug approval process is projected to take 15 years on average, and phases II and III are the most expensive phases of clinical trials. The pre-approval expenditures for a medicine can be as high as US$ 2.56 billion, which further increases to US$ 2.87 billion in the post-approved stage. According to the study titled “Why 90% of Clinical Drug Development Fails and How to Improve It?”, 2022, 90% of clinical drug development fails despite the successful implementation of many strategies. After entering clinical investigations, 9 out of 10 drug candidates fail during phase I, II, and III clinical trials, and the drug approval process. Drug candidates rejected in preclinical stages are not included in the 90% failure rate of the drugs in clinical stages, as they don’t enter the phase I clinical trials. If preclinical drug candidates are included, the failure rate of drug discovery and development rises even higher than 90%. According to analyses of clinical trial data from 2010 to 2017, lacking clinical effectiveness (40–50%), uncontrollable toxicity (30%), poor drug-like qualities (10–15%), no commercial needs, and ineffective strategic planning (10%) are the four major causes of trial failure.

New drug development is both resource and time-intensive, where later clinical stages result in significant costs. The discovery and development of each new medicine that is approved for clinical use is a lengthy, expensive, and challenging process that takes over 10–15 years and costs on average over US$ 1–2 billion. To lower the attrition rate in drug research & development, it is crucial to filter and optimize the absorption, distribution, metabolism, elimination, and toxicity (ADMET) characteristics of pharmaceuticals at an early stage. It has been widely accepted that drug ADMET properties should be considered as early as possible to reduce failure rates in the clinical phase of drug discovery. In vitro and in vivo drug evaluation techniques have reached maturity in preclinical applications, and in silico technologies are gaining vast acceptance to evaluate the relevant properties of drugs in the preclinical stage. The development of software programs and in silico models is further promoting the implementation of ADMET studies. Thus, the increasing need for ADME testing in drug development boosts the pharma ADME testing market.

CMIC HOLDINGS Co., LTD; Charles River Laboratories; WuXi AppTec; Promega Corporation; MERCK KGaA; Agilent Technologies, Inc.; Biovia (Dassault Systèmes); Cyprotex Limited; Bio-Rad Laboratories, Inc.; and IQVIA Inc. are among the leading companies operating in the pharma ADMET testing market. Product launches, product approvals, mergers and acquisitions, and market initiatives are a few strategies adopted by the major market players. For instance, in January 2021, Charles River Laboratories International, Inc. announced a partnership with Valo Health, LLC for transforming the drug discovery and development process. The partnership aims to offer and utilize "Valo's Opal Platform" for small molecule development leveraging closed-loop” in the silico-experimental testing platform.

The pharma ADMET testing market is segmented on the basis of testing type, technology, application, and geography. Based on testing type, the market is segmented into in vivo ADMET testing, in vitro ADMET testing, and in silico ADMET testing. Based on technology, the market is segmented into cell culture, high throughput, molecular imaging, and OMICS technology. Based on application, the global pharma ADMET testing market is segmented into systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and others. By geography, the market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

TABLE OF CONTENTS

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Global Pharma ADMET Testing Market – By Testing Type

1.3.2 Global Pharma ADMET Testing Market – By Technology

1.3.3 Global Pharma ADMET Testing Market – By Application

1.3.4 Global Pharma ADMET Testing Market – By Geography

2. Pharma ADMET Testing Market– Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Global Pharma ADMET Testing Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 North America – PEST Analysis

4.2.2 Europe – PEST Analysis

4.2.3 Asia Pacific – PEST Analysis

4.2.4 Middle East & Africa – PEST Analysis

4.2.5 South & Central America – PEST Analysis

4.3 Expert Opinion

5. Pharma ADMET Testing Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 High Rate of Late-Stage Drug Failure

5.1.2 Increasing Number of Product Approvals and Launches

5.2 Market Restraints

5.2.1 High Cost of ADME Testing Studies

5.3 Market Opportunities

5.3.1 Automation and Advancements in ADME Testing

5.4 Future Trends

5.4.1 The Advent of High-Throughput Screening

5.5 Impact Analysis

6. Pharma ADMET Testing Market– Global Analysis

6.1 Global Pharma ADMET Testing Market Revenue Forecast and Analysis

6.2 Global Pharma ADME Testing Market, By Geography - Forecast, and Analysis

6.3 Market Positioning of Key Players

6.4 Global Pharma ADME Testing Market – Market Potential Analysis, By Region

6.5 Comparative Company Analysis

6.6 Growth Strategy Analysis

6.7 Performance of Key Players

6.7.1 WuXi AppTec

6.7.2 Charles River Laboratories Inc.

7. Pharma ADMET Testing Market Analysis And Forecasts To 2028 – By Testing Type

7.1 Overview

7.2 Global Pharma ADMET Testing Market, By Testing Type 2022 & 2028 (%)

7.3 In Vivo ADMET Testing

7.3.1 Overview

7.3.2 In Vivo ADMET Testing - Revenue and Forecast to 2028 (US$ Million)

7.4 In Vitro ADMET Testing

7.4.1 Overview

7.4.2 In Vitro ADMET Testing Revenue and Forecast to 2028 (US$ Million)

7.5 In Silico ADMET Testing

7.5.1 Overview

7.5.2 In Silico ADMET Testing Revenue and Forecast to 2028 (US$ Million)

8. Pharma ADMET Testing Market Analysis And Forecasts To 2028 – By Technology

8.1 Overview

8.2 Global Pharma ADMET Testing Market, By Technology 2022 & 2028 (%)

8.3 Cell Culture

8.3.1 Overview

8.3.2 Cell Culture - Market Revenue and Forecast to 2028 (US$ Million)

8.4 High Throughput

8.4.1 Overview

8.4.2 High Throughput - Market Revenue and Forecast to 2028 (US$ Million)

8.5 Molecular Imaging

8.5.1 Overview

8.5.2 Molecular Imaging - Market Revenue and Forecast to 2028 (US$ Million)

8.6 OMICS Technology

8.6.1 Overview

8.6.2 OMICS Technology - Market Revenue and Forecast to 2028 (US$ Million)

9. Global Pharma ADMET Testing Market Analysis– By Application

9.1 Overview

9.2 Global Pharma ADMET Testing Market, By Application 2022 & 2028 (%)

9.3 Systemic Toxicity

9.3.1 Overview

9.3.2 Systemic Toxicity - Market Revenue And Forecasts To 2028 (US$ Million)

9.4 Renal Toxicity

9.4.1 Overview

9.4.2 Renal Toxicity - Market Revenue And Forecasts To 2028 (US$ Million)

9.5 Hepatotoxicity

9.5.1 Overview

9.5.2 Hepatotoxicity - Market Revenue And Forecasts To 2028 (US$ Million)

9.6 Neurotoxicity

9.6.1 Overview

9.6.2 Neurotoxicity - Market Revenue And Forecasts To 2028 (US$ Million)

9.7 Others

9.7.1 Overview

9.7.2 Others - Revenue And Forecasts To 2028 (US$ Million)

10. Pharma ADMET Testing Market Revenue and Forecasts to 2028 – Geographical Analysis

10.1 North America: Pharma ADMET Testing Market

10.1.1 Overview

10.1.2 North America: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3 North America: Pharma ADMET Testing Market, by Testing Type, 2020-2028 (US$ Million)

10.1.4 North America: Pharma ADMET Testing Market, by Technology, 2020-2028 (US$ Million)

10.1.5 North America: Pharma ADMET Testing Market, by Application, 2020-2028 (US$ Million)

10.1.6 North America: Pharma ADMET Testing Market, by Country, 2022 & 2028 (%)

10.1.6.1 US: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

10.1.6.1.1 Overview

10.1.6.1.2 US: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

10.1.6.1.3 US: Pharma ADMET Testing Market, by Testing Type, 2020-2028 (US$ Million)

10.1.6.1.4 US: Pharma ADMET Testing Market, by Technology, 2020-2028 (US$ Million)

10.1.6.1.5 US: Pharma ADMET Testing Market, by Application, 2020-2028 (US$ Million)

10.1.6.2 Canada: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

10.1.6.2.1 Overview

10.1.6.2.2 Canada: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

10.1.6.2.3 Canada: Pharma ADMET Testing Market, by Testing Type, 2020-2028 (US$ Million)

10.1.6.2.4 Canada: Pharma ADMET Testing Market, by Technology, 2020-2028 (US$ Million)

10.1.6.2.5 Canada: Pharma ADMET Testing Market, by Application, 2020-2028 (US$ Million)

10.1.6.3 Mexico: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

10.1.6.3.1 Overview

10.1.6.3.2 Mexico: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

10.1.6.3.3 Mexico: Pharma ADMET Testing Market, by Testing Type, 2020-2028 (US$ Million)

10.1.6.3.4 Mexico: Pharma ADMET Testing Market, by Technology, 2020-2028 (US$ Million)

10.1.6.3.5 Mexico: Pharma ADMET Testing Market, by Application, 2020-2028 (US$ Million)

10.2 Europe: Pharma ADMET Testing Market

10.2.1 Overview

10.2.2 Europe: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

10.2.3 Europe: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)

10.2.4 Europe: Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

10.2.5 Europe: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

10.2.6 Europe: Pharma ADMET Testing Market, by Country, 2022 & 2028 (%)

10.2.6.1 Germany: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.1.1 Germany: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.1.2 Germany: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)

10.2.6.1.3 Germany: Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

10.2.6.1.4 Germany: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

10.2.6.2 UK: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.2.1 UK: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.2.2 UK: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)

10.2.6.2.3 UK: Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

10.2.6.2.4 UK: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

10.2.6.3 France: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.3.1 France: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.3.2 France: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)

10.2.6.3.3 France: Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

10.2.6.3.4 France: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

10.2.6.4 Italy: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.4.1 Italy: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.4.2 Italy: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)

10.2.6.4.3 Italy: Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

10.2.6.4.4 Italy: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

10.2.6.5 Spain: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.5.1 Spain: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.5.2 Spain: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)

10.2.6.5.3 Spain: Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

10.2.6.5.4 Spain: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

10.2.6.6 Rest of Europe: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.6.1 Rest of Europe: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.6.2 Rest of Europe: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)

10.2.6.6.3 Rest of Europe: Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

10.2.6.6.4 Rest of Europe: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

10.3 Asia Pacific Pharma ADMET Testing Market Revenue and Forecasts To 2028

10.3.1 Overview

10.3.2 Asia Pacific Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

10.3.3 Asia Pacific: Pharma ADMET Testing Market, by Testing Type, 2019–2028 (US$ Million)

10.3.4 Asia Pacific: Pharma ADMET Testing Market, by Technology, 2019–2028 (US$ Million)

10.3.5 Asia Pacific: Pharma ADMET Testing Market, by Application, 2019–2028 (US$ Million)

10.3.6 Asia Pacific: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Country (%)

10.3.6.1 China: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

10.3.6.1.1 Overview

10.3.6.1.2 China: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

10.3.6.1.3 China: Pharma ADMET Testing Market, by Testing Type, 2019–2028 (US$ Million)

10.3.6.1.4 China: Pharma ADMET Testing Market, by Technology, 2019–2028 (US$ Million)

10.3.6.1.5 China: Pharma ADMET Testing Market, by Application, 2019–2028 (US$ Million)

10.3.6.2 Japan: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

10.3.6.2.1 Overview

10.3.6.2.2 Japan: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

10.3.6.2.3 Japan: Pharma ADMET Testing Market, by Testing Type, 2019–2028 (US$ Million)

10.3.6.2.4 Japan: Pharma ADMET Testing Market, by Technology, 2019–2028 (US$ Million)

10.3.6.2.5 Japan: Pharma ADMET Testing Market, by Application, 2019–2028 (US$ Million)

10.3.6.3 India: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

10.3.6.3.1 Overview

10.3.6.3.2 India: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

10.3.6.3.3 India: Pharma ADMET Testing Market, by Testing Type, 2019–2028 (US$ Million)

10.3.6.3.4 India: Pharma ADMET Testing Market, by Technology, 2019–2028 (US$ Million)

10.3.6.3.5 India: Pharma ADMET Testing Market, by Application, 2019–2028 (US$ Million)

10.3.6.4 South Korea: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

10.3.6.4.1 Overview

10.3.6.4.2 South Korea: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

10.3.6.4.3 South Korea: Pharma ADMET Testing Market, by Testing Type, 2019–2028 (US$ Million)

10.3.6.4.4 South Korea: Pharma ADMET Testing Market, by Technology, 2019–2028 (US$ Million)

10.3.6.4.5 South Korea: Pharma ADMET Testing Market, by Application, 2019–2028 (US$ Million)

10.3.6.5 Australia: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

10.3.6.5.1 Overview

10.3.6.5.2 Australia: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

10.3.6.5.3 Australia: Pharma ADMET Testing Market, by Testing Type, 2019–2028 (US$ Million)

10.3.6.5.4 Australia: Pharma ADMET Testing Market, by Technology, 2019–2028 (US$ Million)

10.3.6.5.5 Australia: Pharma ADMET Testing Market, by Application, 2019–2028 (US$ Million)

10.3.6.6 Rest of Asia Pacific: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

10.3.6.6.1 Overview

10.3.6.6.2 Rest of Asia Pacific: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

10.3.6.6.3 Rest of Asia Pacific: Pharma ADMET Testing Market, by Testing Type, 2019–2028 (US$ Million)

10.3.6.6.4 Rest of Asia Pacific: Pharma ADMET Testing Market, by Technology, 2019–2028 (US$ Million)

10.3.6.6.5 Rest of Asia Pacific: Pharma ADMET Testing Market, by Application, 2019–2028 (US$ Million)

10.4 Middle East & Africa: Pharma ADMET Testing Market

10.4.1 Overview

10.4.2 Middle East & Africa Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

10.4.3 Middle East & Africa: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Testing Type (US$ Million)

10.4.4 Middle East & Africa: Metabolomics Market Revenue and Forecasts to 2028, By Technology (US$ Million)

10.4.5 Middle East & Africa: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

10.4.6 Middle East & Africa Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Country (%)

10.4.6.1 UAE: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

10.4.6.1.1 Overview

10.4.6.1.2 UAE: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

10.4.6.1.3 UAE: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Testing Type (US$ Million)

10.4.6.1.4 UAE: Pharma ADMET Testing Market Revenue and Forecasts To 2028, By Technology (US$ Million)

10.4.6.1.5 UAE: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

10.4.6.2 Saudi Arabia: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

10.4.6.2.1 Overview

10.4.6.2.2 Saudi Arabia: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

10.4.6.2.3 Saudi Arabia: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Testing Type (US$ Million)

10.4.6.2.4 Saudi Arabia: Pharma ADMET Testing Market Revenue and Forecasts To 2028, By Technology (US$ Million)

10.4.6.2.5 Saudi Arabia: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

10.4.6.3 South Africa: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

10.4.6.3.1 Overview

10.4.6.3.2 South Africa Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

10.4.6.3.3 South Africa: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Testing Type (US$ Million)

10.4.6.3.4 South Africa: Metabolomics Market Revenue and Forecasts To 2028, By Technology (US$ Million)

10.4.6.3.5 South Africa: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

10.4.6.4 Rest of Middle East and Africa: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

10.4.6.4.1 Overview

10.4.6.4.2 Rest of Middle East and Africa: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

10.4.6.4.3 Rest of Middle East & Africa: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Testing Type (US$ Million)

10.4.6.4.4 Rest of Middle East & Africa: Metabolomics Market Revenue and Forecasts To 2028, By Technology (US$ Million)

10.4.6.4.5 Rest of Middle East and Africa: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

10.5 South & Central America: Pharma ADMET Testing Market

10.5.1 Overview

10.5.2 South and Central America: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (USD Million)

10.5.3 South and Central America: Pharma ADMET Testing Market, by Testing Type, 2019–2028 (USD Million)

10.5.4 South and Central America: Pharma ADMET Testing Market, by Technology, 2019–2028 (USD Million)

10.5.5 South and Central America: Pharma ADMET Testing Market, by Application, 2019–2028 (USD Million)

10.5.6 South and Central America: Pharma ADMET Testing Market, by country, 2021 & 2028 (%)

10.5.6.1 Brazil: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (USD Million)

10.5.6.1.1 Brazil: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (USD Million)

10.5.6.1.2 Brazil: Pharma ADMET Testing Market, by Testing Type, 2019–2028 (USD Million)

10.5.6.1.3 Brazil: Pharma ADMET Testing Market, by Technology, 2019–2028 (USD Million)

10.5.6.1.4 Brazil: Pharma ADMET Testing Market, by Application, 2019–2028 (USD Million)

10.5.6.2 Argentina: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (USD Million)

10.5.6.2.1 Argentina: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (USD Million)

10.5.6.2.2 Argentina: Pharma ADMET Testing Market, by Testing Type, 2019–2028 (USD Million)

10.5.6.2.3 Argentina: Pharma ADMET Testing Market, by Technology, 2019–2028 (USD Million)

10.5.6.2.4 Argentina: Pharma ADMET Testing Market, by Application, 2019–2028 (USD Million)

10.5.6.3 Rest of South and Central America: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (USD Million)

10.5.6.3.1 Rest of South and Central America: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (USD Million)

10.5.6.3.2 Rest of South and Central America: Pharma ADMET Testing Market, by Testing Type, 2019–2028 (USD Million)

10.5.6.3.3 Rest of South and Central America: Pharma ADMET Testing Market, by Technology, 2019–2028 (USD Million)

10.5.6.3.4 Rest of South and Central America: Pharma ADMET Testing Market, by Application, 2019–2028 (USD Million)

11. Impact of COVID-19 Pandemic on Pharma ADMET Testing Market

11.1 North America: Impact Assessment of COVID-19 Pandemic

11.2 Europe: Impact Assessment of COVID-19 Pandemic

11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic

11.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic

11.5 South and Central America: Impact Assessment of COVID-19 Pandemic

12. Pharma ADMET Testing Market–Industry Landscape

12.1 Overview

12.2 Growth Strategies Done by the Companies in the Market, (%)

12.3 Organic Developments

12.3.1 Overview

12.4 Inorganic Developments

12.4.1 Overview

13. Company Profiles

13.1 CMIC HOLDINGS Co., LTD

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 Charles River Laboratories

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 WuXi AppTec

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

13.3.6 Key Developments

13.4 Promega Corporation

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 Sigma-Aldrich (MERCK KGaA)

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

13.6 Agilent Technologies, Inc.

13.6.1 Key Facts

13.6.2 Business Description

13.6.3 Products and Services

13.6.4 Financial Overview

13.6.5 SWOT Analysis

13.6.6 Key Developments

13.7 Biovia (Dassault Systèmes)

13.7.1 Key Facts

13.7.2 Business Description

13.7.3 Products and Services

13.7.4 Financial Overview

13.7.5 SWOT Analysis

13.7.6 Key Developments

13.8 Cyprotex Limited

13.8.1 Key Facts

13.8.2 Business Description

13.8.3 Products and Services

13.8.4 Financial Overview

13.8.5 SWOT Analysis

13.8.6 Key Developments

13.9 Bio-Rad Laboratories, Inc.

13.9.1 Key Facts

13.9.2 Business Description

13.9.3 Products and Services

13.9.4 Financial Overview

13.9.5 SWOT Analysis

13.9.6 Key Developments

13.10 IQVIA Inc.

13.10.1 Key Facts

13.10.2 Business Description

13.10.3 Products and Services

13.10.4 Financial Overview

13.10.5 SWOT Analysis

13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners

14.2 Glossary of Terms

LIST OF TABLES.

Table 1. North America Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)

Table 2. North America Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (USD Million)

Table 3. North America Pharma ADMET Testing Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 4. US Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)

Table 5. US Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 6. US Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 7. Canada: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)

Table 8. Canada Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 9. Canada Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 10. Mexico: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)

Table 11. Mexico Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 12. Mexico Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 13. Europe: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)

Table 14. Europe: Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 15. Europe: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 16. Germany: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)

Table 17. Germany: Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 18. Germany: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 19. UK: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)

Table 20. UK: Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 21. UK: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 22. France: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)

Table 23. France: Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 24. France: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 25. Italy: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)

Table 26. Italy: Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 27. Italy: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 28. Spain: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)

Table 29. Spain: Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 30. Spain: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 31. Rest of Europe: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)

Table 32. Rest of Europe: Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 33. Rest of Europe: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 34. Asia Pacific: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)

Table 35. Asia Pacific: Pharma ADMET Testing Market, by Technology – Revenue and Forecast to 2028 (US$ Million)

Table 36. Asia Pacific: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 37. China: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)

Table 38. China: Pharma ADMET Testing Market, by Technology – Revenue and Forecast to 2028 (US$ Million)

Table 39. China: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 40. Japan: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)

Table 41. Japan: Pharma ADMET Testing Market, by Technology – Revenue and Forecast to 2028 (US$ Million)

Table 42. Japan: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 43. India: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)

Table 44. India: Pharma ADMET Testing Market, by Technology – Revenue and Forecast to 2028 (US$ Million)

Table 45. India: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 46. South Korea: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)

Table 47. South Korea: Pharma ADMET Testing Market, by Technology – Revenue and Forecast to 2028 (US$ Million)

Table 48. South Korea: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 49. Australia: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)

Table 50. Australia: Pharma ADMET Testing Market, by Technology – Revenue and Forecast to 2028 (US$ Million)

Table 51. Australia: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 52. Rest of Asia Pacific: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)

Table 53. Rest of Asia Pacific: Pharma ADMET Testing Market, by Technology – Revenue and Forecast to 2028 (US$ Million)

Table 54. Rest of Asia Pacific: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 55. Middle East & Africa: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Testing Type (US$ Million)

Table 56. Middle East & Africa: Metabolomics Market Revenue and Forecasts to 2028, By Technology (US$ Million)

Table 57. Middle East & Africa: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 58. UAE: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Testing Type (US$ Million)

Table 59. UAE: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Technology (US$ Million)

Table 60. UAE: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 61. Saudi Arabia: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Testing Type (US$ Million)

Table 62. Saudi Arabia: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Technology (US$ Million)

Table 63. Saudi Arabia: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 64. South Africa Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Testing Type (US$ Million)

Table 65. South Africa: Metabolomics Market Revenue and Forecasts to 2028, By Technology (US$ Million)

Table 66. South Africa: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 67. Rest of Middle East & Africa: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Testing Type (US$ Million)

Table 68. Rest of Middle East & Africa: Metabolomics Market Revenue and Forecasts to 2028, By Technology (US$ Million)

Table 69. Rest of Middle East and Africa: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 70. South and Central America: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (USD Million)

Table 71. South and Central America: Pharma ADMET Testing Market, by Technology – Revenue and Forecast to 2028 (USD Million)

Table 72. South and Central America: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (USD Million)

Table 73. Brazil: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (USD Million)

Table 74. Brazil: Pharma ADMET Testing Market, by Technology – Revenue and Forecast to 2028 (USD Million)

Table 75. Brazil: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (USD Million)

Table 76. Argentina: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (USD Million)

Table 77. Argentina: Pharma ADMET Testing Market, by Technology – Revenue and Forecast to 2028 (USD Million)

Table 78. Argentina: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (USD Million)

Table 79. Rest of South and Central America: Pharma ADMET Testing Market, by Type – Revenue and Forecast to 2028 (USD Million)

Table 80. Rest of South and Central America: Pharma ADMET Testing Market, by Technology – Revenue and Forecast to 2028 (USD Million)

Table 81. Rest of South and Central America: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (USD Million)

Table 82. Organic Developments Done by Companies

Table 83. Inorganic Developments Done by Companies

Table 84. Glossary of Terms

LIST OF FIGURES.

Figure 1. Pharma ADMET Testing Market Segmentation

Figure 2. Pharma ADMET Testing Market, By Region

Figure 3. Global Pharma ADMET Testing Market Overview

Figure 4. In vivo ADMET Testing Segment Held Largest Share of Testing Type Segment in Pharma ADMET Testing Market

Figure 5. Asia Pacific is Expected to Show Remarkable Growth During the Forecast Period

Figure 6. Pharma ADMET Testing Market, by Geography (US$ Million)

Figure 7. Global Pharma ADMET Testing Market - Leading Country Markets (US$ Million)

Figure 8. Global Pharma ADMET Testing Market, Industry Landscape

Figure 9. North America: PEST Analysis

Figure 10. Europe: PEST Analysis

Figure 11. Asia Pacific: PEST Analysis

Figure 12. Middle East & Africa: PEST Analysis

Figure 13. South & Central America: PEST Analysis

Figure 14. Pharma ADMET Testing Market Impact Analysis of Driver and Restraints

Figure 15. Global Pharma ADME Testing Market– Revenue Forecast and Analysis – 2022 - 2028

Figure 16. Global Pharma ADME Testing Market – By Geography Forecast and Analysis – 2022 - 2028

Figure 17. Market Positioning of Key Players in Pharma ADME Testing Market

Figure 18. Global Pharma ADME Testing Market – Market Potential Analysis, By Region

Figure 19. Global Pharma ADME Testing Market – Comparative Company Analysis

Figure 20. Global Pharma ADME Testing Market – Growth Strategy Analysis

Figure 21. Global Pharma ADMET Testing Market, by Testing Type 2022 & 2028 (%)

Figure 22. In Vivo ADMET Testing - Revenue and Forecasts to 2028 (US$ Million)

Figure 23. In Vitro ADMET Testing Revenue and Forecasts to 2028 (US$ Million)

Figure 24. In Silico ADMET Testing Revenue and Forecasts to 2028 (US$ Million)

Figure 25. Global Pharma ADMET Testing Market, by Technology 2022 & 2028 (%)

Figure 26. Cell Culture - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 27. High Throughput - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 28. Molecular Imaging - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 29. OMICS Technology - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 30. Global Pharma ADMET Testing Market, by Application 2022 & 2028 (%)

Figure 31. Systemic Toxicity - Market Revenue And Forecasts To 2028 (US$ Million)

Figure 32. Renal Toxicity - Market Revenue And Forecasts To 2028 (US$ Million)

Figure 33. Hepatotoxicity - Market Revenue And Forecasts To 2028 (US$ Million)

Figure 34. Neurotoxicity - Market Revenue And Forecasts To 2028 (US$ Million)

Figure 35. Others - Revenue And Forecasts To 2028 (US$ Million)

Figure 36. North America: Pharma ADMET Testing Market, by Key Country – Revenue (2022) (US$ Million)

Figure 37. North America Pharma ADMET Testing Market Revenue and Forecast to 2028 (US$ Million)

Figure 38. North America: Pharma ADMET Testing Market, by Country, 2022 & 2028 (%)

Figure 39. US: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

Figure 40. Canada: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

Figure 41. Mexico: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

Figure 42. Europe: Pharma ADMET Testing Market, by Key Country – Revenue (2022) (US$ Million)

Figure 43. Europe: Pharma ADMET Testing Market Revenue and Forecast to 2028 (US$ Million)

Figure 44. Europe: Pharma ADMET Testing Market, by Country, 2022 & 2028 (%)

Figure 45. Germany: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

Figure 46. UK: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

Figure 47. France: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

Figure 48. Italy: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

Figure 49. Spain: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

Figure 50. Rest of Europe: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

Figure 51. Asia Pacific Pharma ADMET Testing Market Overview, by Country (2022)

Figure 52. Asia Pacific: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

Figure 53. Asia Pacific: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Country (%)

Figure 54. China: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

Figure 55. Japan: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

Figure 56. India: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

Figure 57. South Korea: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

Figure 58. Australia: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

Figure 59. Rest of Asia Pacific: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)

Figure 60. Middle East & Africa Pharma ADMET Testing Market Revenue Overview, by Country, 2022 (US$ Million)

Figure 61. Middle East & Africa Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

Figure 62. Middle East & Africa Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Country (%)

Figure 63. UAE: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

Figure 64. Saudi Arabia: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

Figure 65. South Africa: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

Figure 66. Rest of Middle East and Africa: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

Figure 67. South and Central America: Pharma ADMET Testing Market, by Key Country – Revenue (2022) (US$' Million)

Figure 68. South and Central America Pharma ADMET Testing Market Revenue and Forecast to 2028 (USD Million)

Figure 69. South and Central America: Pharma ADMET Testing Market, by country, 2021 & 2028 (%)

Figure 70. Brazil: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (USD Million)

Figure 71. Argentina: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (USD Million)

Figure 72. Rest of South and Central America: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (USD Million)

Figure 73. Impact of COVID-19 Pandemic in North American Country Markets

Figure 74. Impact of COVID-19 Pandemic in European Country Markets

Figure 75. Impact of COVID-19 Pandemic in Asia Pacific Country Markets

Figure 76. Impact of COVID-19 Pandemic in Middle East and Africa Country Markets

Figure 77. Impact of COVID-19 Pandemic in South and Central American Countries

Figure 78. Growth Strategies Done by the Companies in the Market, (%)

The List of Companies - Pharma ADMET Testing Market

1. CMIC HOLDINGS Co., LTD

2. Charles River Laboratories

3. Wuxi AppTec

4. Promega Corporation

5. MERCK KGaA

6. Agilent Technologies, Inc.

7. Biovia (Dassault Systèmes)

8. Cyprotex Limited

9. Bio-Rad Laboratories, Inc.

10. IQVIA Inc.

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the pharma ADMET testing market.

● Highlights key business priorities and focus in order to assist companies to realign their business strategies.

● Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

● Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

TOP